scholarly journals Phyllodes tumor masquerading as a fungating breast mass

2017 ◽  
Vol 2017 (12) ◽  
Author(s):  
Nolan R Bruce ◽  
Jacob T Carlson ◽  
Kayla J Barnard ◽  
Ronda Henry-Tillman
Keyword(s):  
2017 ◽  
Vol 4 (8) ◽  
pp. 2854
Author(s):  
Vasuki R. ◽  
Thanmaran N. B. ◽  
A. K. Kalpana Devi ◽  
Rajesh Menon Moothedath ◽  
Satheesh Kumar M.

Tumor-forming Pseudoangiomatous stromal hyperplasia (PASH) is a rather uncommon breast lesion and only very few cases of tumor-forming PASH were reported from 1986, since the lesion was originally described. In contrast, focal, non-tumor forming PASH may be an incidental microscopic finding in up to 23% of breast biopsies. PASH is a benign proliferative lesion of the breast stroma that is characterized by slit-like pseudovascular spaces lined by endothelial-like spindle cells. It is indeed rare for a discrete breast mass to have PASH as the main pathological feature on histopathology. The breast mass, typically unilateral, was usually diagnosed clinically as a fibroadenoma.When found in tumour form, PASH most commonly manifests as a single, circumscribed, palpable mass in a premenopausal female. The main differential diagnosis histologically are fibroadenoma, phyllodes tumor and angiosarcoma. However, PASH is a benign condition with very good prognosis. Hence possibility of PASH in nodular or tumour form has to be considered when approaching a case of breast lump whose management is different. We report here a case of PASH in tumour form from our Institute.


Medicina ◽  
2021 ◽  
Vol 58 (1) ◽  
pp. 36
Author(s):  
Laura Mustață ◽  
Nicolae Gică ◽  
Radu Botezatu ◽  
Raluca Chirculescu ◽  
Corina Gică ◽  
...  

Phyllodes Tumor (PT) is a rare fibroepithelial breast tumor that can behave differently depending on its biologic features. Traditionally, PTs are classified by their histologic features into benign, borderline, and malignant. In most cases that were reported, all PTs may recur, but only the borderline and malignant PT can metastasize. PT usually occurs as a breast lump or accidental finding on ultrasound (US) examination. The clinical features include a well-defined breast mass, regular or lobulated. The diagnosis is based on the integration of morphology features, but remains challenging, particularly in the distinction from fibroadenomas. We report a case of a 36-year-old patient who presented for a voluminous breast mass, rapidly growing in the past 3–4 months. At presentation, the patient was 19 weeks pregnant. The breast tumor had the clinical and US aspect of PT. A core needle biopsy was obtained, confirming a benign PT, and local excision was performed with no postoperative complications. The final pathology report showed a borderline PT with close resection margins of 1 mm. Immunohistochemistry (IHC) established the diagnosis of malignant PT with heterologous sarcomatous differentiation. The case was discussed in the multidisciplinary tumor board (MDT) and mastectomy was recommended. The patient fully consented but refused surgery at 25 weeks’ gestation, fearing premature delivery. The right breast was closely monitored by US, and at 9 weeks after the first surgery, signs of local recurrence were detected. At 35 weeks’ gestation, right mastectomy was performed, with no perioperative complications. The pregnancy was closely followed up and no complication were found. The final pathology report describes multiples PT recurrences with heterologous sarcomatous differentiation. The pregnancy outcome was uneventful, and the patient delivered a healthy child vaginally at term with no peripartum complication. Postpartum, a computer tomography (CT) examination of the head, thorax, abdomen and pelvis was performed, with no evidence of metastases. Adjuvant chemotherapy and radiotherapy completed the treatment. The follow-up and CT scan showed no metastases or further recurrence 4 years after diagnosis. In conclusion, diagnosis of PT can be difficult, especially because of the easy confusion with fibroadenoma of the breast. There are rare cases when a pathology exam needs further assessment and IHC is recommended for accurate diagnosis. Although malignant PT is rare and accounts for <1% of all breast cancers, the diagnosis and treatment that are recommended are based on the reported cases. Moreover, when complete surgical excision is achieved, the rates of recurrence and distant metastases are low, and adjuvant therapy might not be necessary.


2019 ◽  
Vol 25 (5) ◽  
pp. 988-988
Author(s):  
Mohamed A. Ahmed ◽  
Saba Habis ◽  
Ahmed Mahmoud ◽  
David S. Plurad ◽  
Rasha A.M. Saeed ◽  
...  

2021 ◽  
Vol 8 (11) ◽  
pp. 3460
Author(s):  
Aafrin S. Baldiwala ◽  
Hiren P. Vaidya

Phyllodes is a tumor of breast. This fibro-epithelial lesion occurs in less than 1% of all breast tumors in female. They can be benign, borderline or malignant. It commonly occurs in age group of 45-50 years. It is also known as cystosarcoma phyllodes/ serocystic disease of Brodie. Treatment can be either wide local excision or mastectomy to achieve histologically clear margin. Palpable axillary lymphadenopathy can be identified in up-to 10-15% of patients but less than 1% has pathological positive nodes. Mammography and ultrasonography are main imaging modalities. Here, we present a case of a 14-year-old female presenting with a rapidly enlarging breast mass, which was ultimately found to be a Phyllodes tumor.


1985 ◽  
Vol 21 (6) ◽  
pp. 923
Author(s):  
S Y Chin ◽  
K H Kim ◽  
N M Moon ◽  
Y K Kim ◽  
J J Jang

2013 ◽  
Vol 75 (6) ◽  
pp. 514-517
Author(s):  
Yuka NAKAMURA ◽  
Makoto ICHIMIYA ◽  
Kei NEMOTO ◽  
Yoshitaka NAKAMURA ◽  
Michiya YAMAGUCHI ◽  
...  
Keyword(s):  

2019 ◽  
Vol 1 (23) ◽  
pp. 20
Author(s):  
Anca Zgură ◽  
Laurenţia Galeş ◽  
Elvira Brătilă ◽  
Rodica ANGHEL
Keyword(s):  

Diagnostics ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 825
Author(s):  
Francesco Fortarezza ◽  
Federica Pezzuto ◽  
Gerardo Cazzato ◽  
Clelia Punzo ◽  
Antonio d’Amati ◽  
...  

The breast phyllodes tumor is a biphasic tumor that accounts for less than of 1% of all breast neoplasms. It is classified as benign, borderline, or malignant, and can mimic benign masses. Some recurrent alterations have been identified. However, a precise molecular classification of these tumors has not yet been established. Herein, we describe a case of a 43-year-old woman that was admitted to the emergency room for a significant bleeding from the breast skin. A voluminous ulcerative mass of the left breast and multiple nodules with micro-calcifications on the right side were detected at a physical examination. A left total mastectomy and a nodulectomy of the right breast was performed. The histological diagnosis of the surgical specimens reported a bilateral giant phyllodes tumor, showing malignant features on the left and borderline characteristics associated with a fibroadenoma on the right. A further molecular analysis was carried out by an array-Comparative Genomic Hybridization (CGH) to characterize copy-number alterations. Many losses were detected in the malignant mass, involving several tumor suppressor genes. These findings could explain the malignant growth and the metastatic risk. In our study, genomic profiling by an array-CGH revealed a greater chromosomal instability in the borderline mass (40 total defects) than in the malignant (19 total defects) giant phyllodes tumor, reflecting the tumor heterogeneity. Should our results be confirmed with more sensitive and specific molecular tests (DNA sequencing and FISH analysis), they could allow a better selection of patients with adverse pathological features, thus optimizing and improving patient’s management.


Sign in / Sign up

Export Citation Format

Share Document